Drugs News and Research

RSS
Epic Sciences presents single cell sequencing data from mCRPC patients at 2015 ASCO

Epic Sciences presents single cell sequencing data from mCRPC patients at 2015 ASCO

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

Study shows antibiotic prescriptions in telemedicine exams are as frequent as regular exams

Study shows antibiotic prescriptions in telemedicine exams are as frequent as regular exams

Space Aging study may help identify novel genes linked to longevity

Space Aging study may help identify novel genes linked to longevity

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

ESMO Magnitude of Clinical Benefit Scale assists oncology clinicians in evaluating anti-cancer medicines

ESMO Magnitude of Clinical Benefit Scale assists oncology clinicians in evaluating anti-cancer medicines

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

BioDelivery Sciences calls for new treatment options for opioid addiction

BioDelivery Sciences calls for new treatment options for opioid addiction

Novel biosensor chip measures pH, temperature, drugs and metabolism-related molecules

Novel biosensor chip measures pH, temperature, drugs and metabolism-related molecules

Multiplatform biomarker analysis reveals new therapeutic options for squamous cell anal carcinomas

Multiplatform biomarker analysis reveals new therapeutic options for squamous cell anal carcinomas

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

U.S. District Court enters verdict in favor of faith-based car dealership in challenge to HHS abortion pill mandate

U.S. District Court enters verdict in favor of faith-based car dealership in challenge to HHS abortion pill mandate

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Newer anticoagulant medication may increase risk of GI bleeding in older patients

UB researchers successfully harness E. coli to generate new forms of antibiotics

UB researchers successfully harness E. coli to generate new forms of antibiotics

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.